Drugs / Eligard (TM)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01136226 | Oct 2003 → Jun 2009 | prostate cancer | Chesapeake Urology Research Associates | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eligard (TM) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01136226 ↗ |
| Route | Subcutaneous | “two subcutaneous administration of ELIGARD (TM) 22.5mg” NCT01136226 ↗ |